Biotech Values

[vinmantoo]

The BA.2.86 immune escape, with >35 mutations and amino acid changes compared w/ XBB.1.5 (the "new" booster target, still not available), will be problematic and epitomizes why a variant-chasing strategy doesn't work.
We need a variant-proof vaccine, and many candidates exist.”

The number of amino acid changes alone doesn't mean the new vaccine won't have good efficacy against BA.2.86. We will need analysis of whether the new vaccine generates sufficient neutralizing antibodies. However, the repeated arising of new variants of interest and concern really illustrates the need for good anti-virals. Obviously I hope that EDP-235 can be one of these given my ENTA holdings.